• Roger Cady, Jim Banks, Robert B Nett, Jerome Goldstein, Nathan Bennett, Ira M Turner, Gary E Ruoff, Stephen H Landy, Kathleen Farmer, Márta Juhász, Jeanne Tarrasch, and M Chris Runken.
• Headache Care Center, Springfield, MO, USA. rcady@banyangroupinc.com
• Headache. 2011 Jun 1;51(6):961-70.

ObjectiveTo investigate a broad definition of migraine resolution that extends beyond specific migraine-associated diagnostic symptoms as measured by the Completeness of Response Survey.MethodsConducted at 8 sites, 135 subjects treated migraines with SumaRT/Nap over 2 months. To measure subjects' experiences with SumaRT/Nap compared to their usual migraine medication, the Headache Impact Test, Revised Patient Perception of Migraine Questionnaire, and Completeness of Response Survey were administered at baseline and at 2 months.ResultsThe effects of the study medicine compared to the subjects' usual migraine medicine reached statistical significance in decreasing headache severity, lessening of associated symptoms, and attaining complete relief with a single dose (60.04% of attacks resolved at 2 hours post-treatment).ConclusionCompared to a subject's usual treatment, SumaRT/Nap used early and consistently for treatment of acute migraine offers important clinical improvements, including lessening of associated symptoms beyond International Headache Society criteria.Clinical Trial Registration NumberNCT00893737.© 2011 American Headache Society.

27 keywords...

hide…